食管癌术后辅助治疗的临床价值

摘要/Abstract

摘要：食管癌目前主要的治疗手段仍为手术切除，但术后患者的生存率较低，主要失败模式为局部复发和区域淋巴结转移。术后是否应该行辅助治疗及如何选择方案仍无明确的指南。研究显示Ⅲ期、N1的患者行术后辅助放疗可以提高无瘤生存率及总生存率，靶区范围应根据肿瘤所在的位置来确定。术后辅助化疗方案以顺铂联合5氟尿嘧啶为首选，该方案主要不良反应为胃肠反应和骨髓抑制；术后辅助放化疗的临床价值仍需更多临床研究来支持。

关键词:食管肿瘤,食管切除术,肿瘤辅助疗法

Abstract:Surgery is the standard therapy for esophageal cancer, however, the postoperative overall survival rate is still disappointed. Local recurrence and regional lymph node metastasis are the main failure models. The optimal therapeutic modality for these patients with radical resection remains unclear. Some researches indicate that patients with stage Ⅲ, N1 can benefit from postoperative radiotherapy, which can improve the diseasefree survival and overall survival ratio. The irradiation field depends on the site of tumor removal (tumor bed) during surgery. The cisplatin plus 5fluorouracil chemotherapy regimen seems as the preferred for postoperative adjuvant chemotherapy, the mainly adverse reactions are digestive tract reactions and myelosuppression. The clinical value of postoperative adjuvant chemoradiotherapy still needs more clinical trials to support.

Key words:Esophageal neoplasms,Esophagectomy,Neoadjuvant therapy

方伟生，赖沛宝，王小艳等. 食管癌术后辅助治疗的临床价值[J]. 国际肿瘤学杂志, 2014, 41(1): 34-37.

Fang Weisheng, Lai Peibao, Wang Xiaoyan, et al. Clinical value of adjuvant therapy for esophageal cancer after radical resection[J]. Journal of International Oncology, 2014, 41(1): 34-37.

参考文献

［1］ Krasna MJ. Multimodality therapy for esophageal cancer ［J］. Oncology, 2010, 24(12):11341138. ［2］ Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, et al. Esophageal Cancer: An update ［J］. Int J Surg, 2010, 8 (6):417422. ［3］ Jingu K, Matsushita H, Takeda K, et al. Longterm results of radiotherapy combined with nedaplatin and 5fluorouracil for postoperative locoregional recurrent esophageal cancer: update on a phase Ⅱ study［J］. BMC Cancer, 2012, 12:542. ［4］ Calvo FA, Sole CV, Obregón R, et al. Postchemoradiation resected locally advanced esophageal and gastroesophageal junction carcinoma: longterm outcome with or without intraoperative radiotherapy［J］. Ann Surg Oncol, 2013, 20(6):19621969. ［5］ Rodriguez CP, Adelstein DJ, Rice TW, et al. A phase Ⅱ study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer ［J］. J Thorac Onocl, 2010, 5(2):229235. ［6］ Schreiber D, Rineer J, Vongtama D, et al. Impact of postoperative radiation after esophagectomy for esophageal cancer［J］. J Thorac Oncol, 2010, 5(2):244250. ［7］ Chen J, Zhu J, Pan J, et al. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus［J］. Ann Thorac Surg, 2010, 90(2):435442. ［8］ Akutsu Y, Matsubara H. The significance of lymph node status as a prognostic factor for esophageal cancer［J］. Surg Today, 2011, 41(9):11901195. ［9］ Chen J, Pan J, Zheng X, et al. Number and location of positive nodes, postoperative radiotherapy, and survival after esophagectomy with threefield lymph node dissection for thoracic esophageal squamous cell carcinoma. ［J］. Int J Radiat Oncol Biol Phys, 2010, 82(1):475482. ［10］ Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent ［J］. Ann Surg, 2008, 247(2):365371. ［11］ Greenstein AJ, Litle VR, Swanson SJ, et al. Prognostic significance of the number of lymph node metastases in esophageal cancer ［J］. J Am Coll Surg, 2008, 206(2):239246. ［12］ Cai WJ, Xin PL. Pattern of relapse in surgical treated patients with thoracic esophageal squamous cell carcinoma and its possible impact on target delineation for postoperative radiotherapy ［J］. Radiother Oncol, 2010, 96(1):104107. ［13］刘俊, 吕长兴, 王家明, 等. 104例胸段食管癌左胸路径术后局部复发规律及放疗靶区范围探讨［J］. 中华放射肿瘤学杂志, 2013, 22(2):111114. ［14］陈俊强, 潘建基, 陈明强, 等. 胸段食管鳞癌淋巴结转移数和区域与术后放疗价值的临床研究［J］. 中华放射肿瘤学杂志, 2010, 19(2):105109. ［15］章文成, 王奇峰, 肖泽芬, 等. 胸段食管鳞癌根治术后失败模式对放疗野设计的指导作用［J］. 中华放射肿瘤学杂志, 2012, 21(1):3841. ［16］ Tachimori Y, Nagai Y, Kanamori N, et al. Pattern of lymph node metastases of esophageal squamous cell carcinoma based on the anatomical lymphatic drainage system ［J］. Dis Esophagus, 2011, 24(1):3338. ［17］ Fenkell L, Kaminsky I, Breen S, et al. Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus［J］. Radiother Oncol, 2008, 89(3):287291. ［18］ Asakura H, Hashimoto T, Zenda S, et al. Analysis of dosevolume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer ［J］. Radiother Oncol, 2010, 95(2):240244. ［19］ Wang J, Wei C, Tucker SL, et al. Predictors of Postoperative Complications After Trimodality Therapy for Esophageal Cancer［J］. Int J Radiat Oncol Biol Phys, 2013, 86(5):885891. ［20］ Zhang J, Chen HQ, Zhang YW, et al. Adjuvant chemotherapy in oesophageal cancer: a metaanalysis and experience from the Shanghai Cancer Hospital［J］. J Int Med Res, 2008, 36(5):875882. ［21］ Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated metaanalysis［J］. Lancet Oncol, 2011, 12(7):681692. ［22］ Kranzfelder M, Schuster T, Geinitz H, et al. Metaanalysis of neoadjuvant treatment modalities and definitive nonsurgical therapy for oesophageal squamous cell cancer［J］. Br J Surg, 2011, 98(6):768783. ［23］王肇炎. 食管癌药物治疗的前景困难及对策［J］. 中华肿瘤杂志, 2011, 33(2):157159. ［24］ Yamamoto Y, Yamai H, Seike J, et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, Fluorouracil, and cisplatin［J］. Ann Surg Oncol, 2012, 19(3):757765. ［25］ Neuner G, Patel A, Suntharalingam M. Chemoradiotherapy for Esophageal Cancer［J］. Gastrointest Cancer Res, 2009, 3(2):5765. ［26］ Adelstein DJ, Rice TW, Rybicki LA, et al. Mature results from a phase Ⅱ trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction［J］. J Thorac Oncol, 2009, 4(10):12641269. ［27］ Wu S, Deng X, Zhang P, et al. Phase Ⅱ study of postoperative chemoradiotherapy for esophageal carcinoma［J］. J Clin Oncol, 2009, 27 Suppl 15:e15606 ［28］ Yeh HL, Hsu CP, Lin JC, et al. A retrospective study of postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma［J］. Form J Surg, 2012, 45:172177.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[3]	万芳, 杨钢, 李睿, 万启晶.食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[4]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安.新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[5]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[6]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟.基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[7]	山东省医学会肺癌食管癌多学科联合委员会.山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[8]	徐放, 朱文钿.肝细胞癌合并微血管侵犯术后辅助治疗现状[J]. 国际肿瘤学杂志, 2023, 50(5): 304-309.
[9]	冀世玉, 张明鑫, 谢华红, 白渊, 王彤.不同支架治疗晚期食管癌患者的疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 76-81.
[10]	巩合义, 伊艳, 张健, 李宝生.局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.
[11]	吴浦嫄, 祁亮, 王涛, 史敏科, 孙雨薇, 王立峰, 刘宝瑞, 闫婧, 任伟.基于高频复发区改良临床靶区的术后放疗在食管鳞状细胞癌中的疗效研究[J]. 国际肿瘤学杂志, 2022, 49(8): 464-472.
[12]	戴李宸, 胡莉钧, 于静萍.尼妥珠单抗治疗食管鳞状细胞癌的应用进展[J]. 国际肿瘤学杂志, 2022, 49(8): 484-489.
[13]	夏玲玲, 陈永顺, 李彬, 宁婷婷, 张蔡羽天.pN₊食管鳞状细胞癌患者R0切除术后放化疗与化疗的安全性及有效性比较[J]. 国际肿瘤学杂志, 2022, 49(6): 334-339.
[14]	叶倩, 凌志, 刘申香, 路国涛, 殷旭东.肌肉减少症对老年食管癌患者根治性放疗临床疗效及预后的影响[J]. 国际肿瘤学杂志, 2022, 49(4): 199-205.
[15]	周剑烽, 王铁君.食管癌的靶向治疗及免疫治疗[J]. 国际肿瘤学杂志, 2022, 49(4): 237-242.